The molecular profile of Merkel cell carcinoma (MCC) differs depending upon whether the malignancy is driven by ultraviolet (UV) light or by a virus and can be correlated with responses to immunotherapy, according to recent study findings.
Additionally, 57 of the patients with advanced or metastatic MCC who were treated at Moffitt were analyzed in the clinical cohort, and 38 received an immune checkpoint inhibitor.
Click to Enlarge
In the clinical cohort, the most common diagnosis was stage IIIB or IV MCC (78.9%). Almost half of the immunotherapy-treated patients (47%) received immune checkpoint inhibition with pembrolizumab (Keytruda) monotherapy, and 26% received avelumab (Bavencio) monotherapy. Radiation therapy was given prior to immunotherapy for 79% of patients, and 16% of patients did not receive any radiation. Most patients were treated with immunotherapy in the first-line (32%) or second-line (40%) setting; 2 patients were treated in the fifth-line setting.Outcomes of Genomic Profiling of Tumor Samples
... to read the full story